Open AccessTwo year persistent treatment effect in reducing nasal symptoms of cat allergy after 4 doses of Cat‐PAD, the first in a new class of synthetic peptide immuno‐regulatory epitopes
Author(s) -
Hafner Roderick,
Couroux Peter,
Armstrong Kristen,
Patel Deepen,
Larche Mark,
Haumann Brett
Publication year - 2013
Publication title -
clinical and translational allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.979
H-Index - 37
ISSN - 2045-7022
DOI - 10.1186/2045-7022-3-s2-o7
Subject(s) - medicine , placebo , nose , allergy , allergen , surgery , immunology , pathology , alternative medicine
Background Treatment with Cat-PAD (also known as ToleroMune Cat, the first in a new class of synthetic peptide immuno-regulatory epitopes), in an Environmental Exposure Chamber (EEC) model of cat allergy showed a persistent treatment effect one year [1] and two years [2] after administration of only 4 injections over 12 weeks. Here we report the differences in Total Nasal Symptom Scores (TNSS) between Cat-PAD treatment arms and placebo two years after treatment started.